Geron Corp (GERN) – StreetInsider.com Reports
-
Geron Corp (GERN) Prices $150M Share and Warrant Offering at $3/sh
-
Increasing unusual put option volume: UAA SOUN EH GERN TAL EN TELL STNE GOOS BIIB VRT VKTX GRPN MSOX PAGS ACHR
-
Increasing unusual call option volume: SMR SOUN GERN AMBC AM CDLX UMC AQST
-
Geron Corporation (GERN) PT Raised to $5 at Needham, 'anticipate imetelstat will receive the go-ahead on or prior to its June 16 PDUFA date'
-
Geron Corp (GERN) option IV into Geron reports FDA advisors vote in favor of benefit/risk of imetelstat
-
Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs
-
After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
-
Geron Corp (GERN) Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat
-
Geron Corp (GERN) Halted, News Pending
-
Geron Corp (GERN) option IV into FDA Oncologic Drugs Advisory Committee meeting
-
Increasing unusual option volume: GERN REI CMI ATMU SOUN ALGM TMC RXT
-
Geron Corp (GERN) option implied volatility into FDA Oncologic Drugs Advisory Committee meeting
-
Geron Corp (GERN) option IV up into meeting
-
Geron Corp (GERN) call put ratio 1.1 call to 1 put into FDA Oncologic Drugs Advisory Committee meeting
-
Geron Corp (GERN) option IV elevated
-
Geron Corp (GERN) option IV above 200
-
Geron Corporation (GERN) PT Lowered to $4.50 at Baird
-
Geron Corp (GERN) Tops Q4 EPS by 2c ; Provides Outlook
-
Geron Corp (GERN) Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
-
Geron Corp (GERN) Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
-
Geron Corp (GERN) announces $100M ATM offering
-
Geron Corp (GERN) Tops Q3 EPS by 2c
-
Geron Corp (GERN) Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
-
Goldman Sachs just upgraded this SMID-cap biopharma stock and it's surging
-
Oracle, UPS, Acelryin fall premarket; Apple, WestRock rise
-
Goldman Sachs Upgrades Geron Corporation (GERN) to Buy, 'buying opportunity ahead of 2024 launch'
-
Geron Corp (GERN) Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer,
-
This biopharma stock was added to Wedbush's best ideas list and has 150% upside
-
Geron Corp (GERN) Added to Wedbush Best Idea List
-
Geron Corp (GERN) Announces PDUFA Date of June 16th, 2024 for Imetelstat NDA
-
Geron Corp (GERN) Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
-
Geron Corp (GERN) Misses Q2 EPS by 21c
-
Geron Corp (GERN) Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
-
Geron Corp (GERN) Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
-
Increasing unusual call option volume
-
Geron Corporation (GERN) PT Raised to $4 at Goldman Sachs
-
Geron Corp (GERN) Tops Q1 EPS by 3c
-
Goldman Sachs Starts Geron Corporation (GERN) at Neutral, 'Commercial opportunity for imetelstat reflected in valuation'
-
Geron Corporation (GERN) PT Raised to $5 at B.Riley
-
Geron Corporation (GERN) PT Raised to $5 at Stifel
-
Geron Corp (GERN) Prices Upsized 55.88M Share Offering at $2.45/sh
-
After-hours movers: Geron lower on offering, Inter Parfums gains on raised guidance
-
Geron Corp (GERN) Announces $175M Proposed Public Offering of Common Stock
-
Geron Corp (GERN) Files Prospectus to Offer Common Stock, Preferred Stock, Debt Securities and Warrants
-
Geron Corporation (GERN) PT Raised to $6 at Wedbush
-
Increasing unusual call volume: GERN FORG WE AU MAXN SMMT AUPH MLCO VST BBD
-
Stifel Reiterates Buy Rating on Geron Corporation (GERN), 'we remain buyers here'
-
Despite 50% surge in Geron (GERN), Stifel remains a buyer
-
Geron Corp (GERN) climbs 56% after announcing IMerge Phase 3 trial met its primary efficacy endpoint
-
Geron Corp (GERN) IMerge Phase 3 trial met its primary efficacy endpoint
Back to GERN Stock Lookup